Lenisolone

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lenisolone

Property Description
Active ingredient Prednisolone Acetate
Form Sterile Aqueous Suspension
Pharmacological class Glucocorticoid (Corticosteroid)
Common use Suppression of local inflammation and swelling
Origin Synthetic

What is Lenisolone and its Pharmacological Class?

Lenisolone is a potent pharmaceutical preparation whose active ingredient is Prednisolone Acetate. This compound is classified as a synthetic adrenocortical steroid, belonging to the Glucocorticoid category within the broader class of Corticosteroids. The product is manufactured as a single-ingredient formulation, allowing its action to be singularly focused on the powerful anti-inflammatory properties of this specific structure. Prednisolone Acetate is consistently recognized in clinical practice as an effective topical agent with a medium-potency classification. This indicates that the preparation is designed for an intense and targeted local action against inflammatory processes.


Composition and Pharmaceutical Form of Lenisolone

Lenisolone is characterized by its dosage form as a sterile suspension intended for topical delivery. A suspension is a liquid system where fine, solid particles of the active drug, Prednisolone Acetate, are evenly distributed throughout an aqueous vehicle. This physical form is crucial for the medicine's functionality because it facilitates an extended contact time on the application site. This differentiating feature creates a functional reservoir that allows for the gradual release of the anti-inflammatory agent, which is necessary to sustain therapeutic management in localized inflammatory responses.


General Purpose: Why is Lenisolone Used?

The general therapeutic purpose of Lenisolone is to leverage its intense anti-inflammatory and immunosuppressant capabilities to rapidly control acute local tissue reactions. Its active compound functions as a glucocorticoid receptor agonist, fundamentally modulating the body’s inflammatory cascade at a cellular level. This mechanism is recognized for its ability to effectively mitigate the physical manifestations of severe tissue reaction, including localized swelling, heat, and redness. The primary benefit of the preparation is the rapid, concentrated suppression of inflammation directly where the body's reaction is most excessive.

Regulatory References

  1. NIH Prednisolone Acetate entry
  2. DailyMed entry on Prednisolone Acetate suspension

What side effects are possible with Lenisolone?

Possible Side Effects and Safety Information

The safety profile for this ophthalmic suspension is based strictly on documentation from regulatory authorities, reflecting the known effects of local corticosteroid exposure, primarily categorized as Eye Disorders. The safety profile is structured around time-related consequences and population-specific considerations.

Documented Adverse Reactions

The most significant adverse reactions officially listed in regulatory documents are often associated with prolonged use (typically ten days or longer). These include the elevation of Intraocular Pressure (IOP), which may progress to Glaucoma with damage to the optic nerve. Another duration-dependent effect is the formation of Posterior Subcapsular Cataracts.

Transient symptoms immediately associated with the application, such as burning and stinging, are also listed. Less frequently documented systemic reactions, categorized under Endocrine System Disorders, include the potential for Adrenal Suppression or Systemic Hypercorticoidism, which are rare and typically linked to intensive, long-term application.

Serious Safety Concerns and Restrictions

Serious concerns documented in official labeling include the risk of Perforation of the Globe in patients with pre-existing thinning of the cornea or sclera, or due to long-term use. The preparation may also mask or exacerbate Secondary Ocular Infections (fungal, viral), which are considered a key safety limitation.

Safety notes for specific groups address the pediatric population, where the possibility of Adrenal Suppression should be considered with prolonged use. Furthermore, the excipient Sodium Bisulfite is explicitly documented as a potential source of allergic-type reactions, including anaphylaxis or asthmatic episodes, in susceptible individuals.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Lenisolone (Prednisolone Acetate) addresses potential overdose risks by distinguishing between acute exposure and chronic systemic effects resulting from prolonged use. Acute ocular overdose or accidental ingestion of the topical suspension is generally classified as unlikely to cause acute problems or toxic effects.

The serious manifestations of overdose are associated with intensive or long-term continuous use, which may lead to significant systemic absorption. These regulator-documented signs include the development of Systemic Hypercorticoidism and clinical presentation resembling Cushing's syndrome.

Life-Threatening Outcomes and Required Action

The most severe outcome documented is Adrenal suppression, specifically Hypothalamic-pituitary-adrenal (HPA) axis suppression. This condition is considered a serious medical emergency.

Patients must seek IMMEDIATE medical attention at the first sign of an adverse drug reaction or if systemic effects are suspected. The standard approach is symptomatic and supportive treatment. If accidental ingestion occurs, the officially documented action is to drink fluids to dilute the contents. In confirmed cases of HPA axis suppression, medical management requires gradual withdrawal of the product.

  • Population Note: Regulatory documents specify that very young children are particularly susceptible to adrenal suppression and Cushing's syndrome from frequent use.

Therapeutic Uses of Lenisolone

What Lenisolone Treats: Main Uses and Benefits

Lenisolone is considered relevant in clinical settings that involve acute or unstable symptom patterns, particularly those affecting the anterior segment of the eye, including the iris, cornea, and conjunctiva. The preparation may be part of symptomatic management across conditions characterized by periods of heightened symptoms, such as non-infectious uveitis and severe allergic conjunctivitis. It is generally applied in contexts involving inflammatory or irritative processes, including inflammation following injury, allergy, heat, or chemicals.

The preparation contributes to improved comfort during periods of heightened symptoms, and may assist with managing pronounced manifestations like ocular redness, burning, and swelling that interfere with daily comfort. Lenisolone may also be applied when appropriate in scenarios where additional management of discomfort is required, such as the postoperative recovery phase following procedures like cataract surgery. This use supports general well-being during symptomatic phases, assisting with maintaining functional stability by easing symptoms related to inflammatory states.

“The medication may be relevant in contexts marked by increased discomfort or tension, supporting patients during difficult episodes by easing the intensity of localized ocular discomfort and inflammation.”


Quick Fact: Support for Symptomatic Ocular Discomfort Lenisolone is applied when appropriate for managing symptoms related to inflammatory or irritative states, including iritis, keratitis, and allergic eye reactions.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Lenisolone?

The population eligibility for using Lenisolone (Prednisolone Acetate Ophthalmic Suspension) is determined strictly by regulatory guidelines, focusing on absolute contraindications and mandatory use restrictions.


Absolute Contraindications (Must Not Use)

Lenisolone is contraindicated in patients with active ocular infections caused by viruses (including epithelial herpes simplex keratitis, vaccinia, and varicella), fungi, or mycobacteria (including tuberculosis of the eye), as specified in official regulatory documents. Individuals with a known or suspected hypersensitivity to any component of the preparation must also not use it.


Population and Condition Restrictions

Population Group Regulatory Status and Constraint
Pediatric Population Safety and efficacy have not been established for all children, generally restricting use.
Pregnancy Use is restricted to cases where the potential benefit officially justifies the potential risk to the fetus.
Lactation Use requires a decision to either discontinue nursing or discontinue the drug.
Glaucoma/Ocular Herpes Use is conditional, requiring great caution and frequent monitoring of intraocular pressure or corneal status.

Official labeling allows use in adults and older adults for short-term management of steroid-responsive ocular inflammation, provided no contraindications are present.

What should I know about interactions with other medicines?

The documented interaction profile for Lenisolone (Prednisolone Acetate Ophthalmic Suspension) is governed by systemic metabolic risk, specifically involving pharmacokinetic interactions. Medicinal products classified as CYP3A Inhibitors are the categories with formally documented interaction risk, with cobicistat-containing products being explicitly listed in regulatory documentation.

Interaction-Related Restrictions

Co-treatment with strong CYP3A inhibitors is officially expected to increase the systemic exposure of the corticosteroid, which carries an increased risk of systemic side-effects. Regulatory documents state that this combination should be strictly avoided unless the potential clinical benefit outweighs this increased risk. If co-administration is deemed necessary, official documentation specifies that patients must be subject to monitoring for signs of systemic corticosteroid effects.

Interaction Profile Classification

The severity of this interaction is classified as a clinically significant risk requiring avoidance or cautious use with monitoring. No other major interaction categories are explicitly documented in the official regulatory text for this ophthalmic formulation. This profile includes no formally stated timing-based administration rules, no population-specific interaction cautions (such as those for hepatic impairment), and no documented interactions with food, alcohol, or herbal products. The regulatory structure for this product focuses solely on the one documented metabolic risk pathway.

Mechanism of Action

Mechanism of Action: Molecular Targets and Cascades

Lenisolone acts via its active ingredient, a synthetic steroid that functions as an agonist for the Glucocorticoid Receptor ( GR), a high-affinity intracellular target. The activated drug-receptor complex enters the cell nucleus to modulate gene expression, either by turning off pro-inflammatory genes (transrepression of factors like NF-kappa B) or turning on anti-inflammatory genes (transactivation). This process results in sustained cellular modulation of gene expression, affecting downstream pathway activity.

A direct result of this genomic action is the increased synthesis of the protein Lipocortin-1, which indirectly inhibits the enzyme Phospholipase A2 ( PLA2). By blocking PLA2, the drug prevents the release of Arachidonic Acid, thereby reducing the generation of inflammatory mediators like Prostaglandins and Leukotrienes.

Simultaneously, the mechanism alters the function of local blood vessel walls by decreasing the expression of adhesion molecules. This modulates the vessel structure, reducing capillary permeability, and prevents immune cells (leukocytes) from migrating out of the vessels and into the tissue. This physiological consequence reduces the rate of plasma and cell extravasation into the tissue, modulating fluid volume at the site of action.

Dosage and Administration Information

Official Administration Guidelines for Lenisolone (Prednisolone)

Lenisolone is a corticosteroid for systemic use that must be administered orally. The official instructions for its use emphasize that the dosage is variable and highly individualized based on the severity of the condition and the patient’s response to the medicine, rather than a fixed standard.

Dosing and Frequency Rules

Guideline Official Instruction
Route of Administration Oral (Tablet, Oral Solution, or Orally Disintegrating Tablet)
Initial Dosage Range Typically 5 mg to 60 mg per day (prednisolone base or equivalent).
Maintenance Dose The initial dose must be adjusted or maintained until a satisfactory response is noted; then, it is decreased in small decrements to the lowest dosage that maintains an adequate clinical response.
Frequency The daily dose may be given once a day or in divided doses. The drug's biological half-life makes it suitable for alternate-day administration regimens.
Timing with Meals The medication should be taken with food to avoid or minimize gastrointestinal irritation.
Pediatric Use Dosing for children is governed by the same considerations as for adults (disease severity and patient response) and not by strict adherence to the ratio indicated by age or body weight.

Special Procedural Conditions

Discontinuation (Tapering): If you have been taking Lenisolone for a long duration or at a high dose, the medication must be withdrawn gradually to prevent a potential lack of naturally produced steroids in the body. A healthcare provider will implement a controlled tapering schedule to slowly reduce the dose. Do not suddenly stop taking this medicine unless instructed by a healthcare professional.

Missed Dose: If a dose is missed, take it as soon as you remember. However, if it is almost time for the next scheduled dose, skip the missed one and continue your regular schedule. Do not take a double dose to make up for a missed dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lenisolone


Evidence for Use in Acute Anterior Uveitis

Lenisolone was studied in adult populations diagnosed with non-infectious inflammation in the front portion of the eye (the anterior uvea). Research examined this condition, which is characterized by fluctuating or episodic manifestations. The primary study design utilized was the Randomized Controlled Trial (RCT), often structured as comparisons against other active topical agents.

The trials examined short-term symptom outcomes. Studies monitored specific measurements, including AC cell scores and the tracking of subjects who achieved a specific zero measurement for anterior chamber cell count during the study period. Because the product was evaluated in comparison to other active agents, evidence from direct comparisons against a placebo is less prevalent in the primary trials. Long-term effects are not fully established, and follow-up durations were limited.


Evidence for Use Following Ocular Surgery

This evidence includes systematic reviews and pooled analyses of trials that monitored outcomes after surgical procedures, such as cataract surgery. The research examined outcomes linked to inflammatory or irritative states, including measures of global inflammation and the tracking of measurements related to cellular activity in the eye's anterior chamber. The study designs used were Randomized Controlled Trials (RCTs).

Key research studies monitored outcomes in both adults and pediatric patients who were undergoing ocular surgery. Trials frequently described the product as an active comparator for evaluating newer anti-inflammatory drops. However, evidence quality varies across studies, and high variability (or heterogeneity) was observed in some studies concerning the measured changes in inflammation metrics at specific check-up times.


What Research Gaps and Uncertainties Remain

Research into Lenisolone provides context but not individual predictions, and the evidence highlights what is known—and what is still uncertain. A key limitation across the research is that many trials use an active-control design, meaning the product is compared to another active treatment rather than an inactive substance (placebo). Therefore, comparative evidence is less established or less prevalent in some contexts. Furthermore, evidence is limited regarding long-term outcomes, meaning the impact beyond the initial treatment period is not well characterized.

Key Studies & References

  1. Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model (Source for Allergic Conditions/CAC Model/Placebo-Controlled Data)

Frequently Asked Questions (FAQ)

Common questions about Lenisolone (FAQ)

Q: How quickly does Lenisolone start to reduce inflammation?

A: According to official product information, systemic corticosteroids like Lenisolone can begin to work relatively quickly to reduce inflammation, often showing initial effects within a few hours to a day. However, achieving the full clinical benefit and resolution of symptoms may take a longer period of time.

Q: Can Lenisolone make you feel tired or fatigued?

A: Official regulatory documents list fatigue and unusual weakness as possible side effects associated with taking corticosteroids like Lenisolone. If persistent or severe tiredness occurs, patients are generally advised to discuss this with their healthcare provider.

Q: What are the most frequent mild side effects of Lenisolone?

A: For the ophthalmic (eye drop) suspension, common and transient mild effects include temporary burning or stinging when the drop is applied. For systemic use, common effects can include a headache, feeling restless, and an increase in appetite.

Q: Is it common to have trouble sleeping when taking Lenisolone?

A: Yes, regulatory information indicates that insomnia, or difficulty sleeping, is a known central nervous system side effect of corticosteroids. Awareness of this potential effect may be helpful during treatment.

Q: Is Lenisolone known to cause weight gain?

A: Yes, official prescribing information states that common side effects of systemic corticosteroids include increased appetite and weight gain. This may be due to fluid retention or changes in fat distribution that occur with the medication.

Q: Does Lenisolone affect your mood or cause mood swings?

A: Official sources confirm that behavioral and mood disturbances are possible side effects of corticosteroids. These can include mood swings, feelings of euphoria, depression, or changes in personality.

Q: Is it true that Lenisolone can weaken bones over time?

A: Yes, official warnings associated with prolonged corticosteroid use mention the risk of a decrease in bone mineral density, a condition known as osteoporosis. This risk reinforces the principle that treatment should use the lowest effective dose for the shortest duration necessary.

Q: Is there a best time of day to take Lenisolone for better effect?

A: For systemic use, official guidelines state the daily dose may be taken once a day or divided into multiple doses. Healthcare providers commonly consider administration in the morning, which aligns with the body's natural corticosteroid rhythm. Patients should follow the timing instructed by their prescriber.

Q: How long does Lenisolone stay in your system after stopping it?

A: The active compound, prednisolone, is largely eliminated from the bloodstream within approximately 16 to 22 hours after the last dose. However, the medication's biological effects may persist, which is why gradual dose reduction (tapering) is often necessary after long-term use.

Q: Is Lenisolone used for skin conditions, and if so, which ones?

A: Systemic corticosteroids like Lenisolone are indicated for treating various dermatologic (skin) diseases. Its anti-inflammatory properties are used to suppress severe reactions and conditions affecting the skin.

Q: Can I take Lenisolone if I have high blood pressure?

A: Official warnings state that corticosteroids can cause elevated blood pressure and fluid retention. Therefore, close monitoring of blood pressure is typically advised for patients with pre-existing high blood pressure during treatment.

Q: Is it safe to take Lenisolone for a long period of time?

A: While treatment duration is individualized, regulatory documents advise using the lowest effective dose for the shortest duration necessary. This practice helps mitigate the increased risk of certain serious side effects associated with long-term use, such as decreased bone density and suppression of the body's natural steroid production.

Q: Is Lenisolone ever prescribed for severe allergies?

A: Yes, systemic Lenisolone is officially indicated for the treatment of various severe allergic states where its potent anti-inflammatory and immunosuppressive actions are necessary to control the reaction.

Q: Why do people say Lenisolone can affect the immune system?

A: Lenisolone is a corticosteroid, and official warnings explain that this class of drug can decrease the body’s normal immune response. This action can increase the risk of developing new infections or worsening existing ones.

Q: What are the signs of a more serious, but rare, side effect from Lenisolone?

A: Though rare, serious systemic side effects can include signs like bloody or black, tarry stools, or new, severe mood and behavioral changes such as visual hallucinations. If any signs of a serious reaction occur, contacting a healthcare professional immediately is generally recommended.

Q: Is Lenisolone safe for older adults or seniors?

A: Official information indicates that while there is no specific data limiting its use in older adults, older patients may be more sensitive to certain effects. Healthcare providers often tailor the dose and monitoring plan carefully for this population.

Q: Are there any known interactions between Lenisolone and alcohol?

A: While regulatory documents do not list a specific drug-drug interaction warning for alcohol, both alcohol and corticosteroids can cause side effects like stomach irritation and immune suppression. Using them together may potentially heighten these effects.

Q: Can Lenisolone cause stomach upset or heartburn?

A: Yes, gastrointestinal issues are known risks associated with systemic corticosteroids, including stomach discomfort, heartburn, and in rare cases, more severe issues like ulcers. Official administration instructions often recommend taking the medication with food to help minimize general gastrointestinal irritation.

Q: Are children ever given Lenisolone, and for what conditions?

A: Yes, systemic Lenisolone is indicated for use in children for conditions such as allergic states, inflammatory conditions, and certain blood disorders. Treatment plans for children are highly individualized based on their specific condition and response.

Q: Is Lenisolone available as a generic medicine?

A: Yes, the active ingredient in Lenisolone, Prednisolone, is a well-established medicine that is widely available in generic form.

Q: What diseases or conditions does Lenisolone primarily treat?

A: Lenisolone (systemic Prednisolone) is indicated for a broad array of conditions that involve inflammation and immune response. This includes allergic states, various inflammatory diseases, and certain autoimmune conditions.

Q: Does taking Lenisolone require any special blood tests?

A: For patients on long-term corticosteroid therapy, monitoring is required. This often includes blood tests to check blood pressure, blood glucose levels, electrolytes (sodium and potassium), and assessments of bone mineral density.

Q: Is it normal to feel a bit shaky or restless after taking Lenisolone?

A: Official adverse reaction reports confirm that feelings of excitement, restlessness, and neurological effects such as tremor or vertigo are possible side effects of corticosteroids.

Q: Can Lenisolone affect blood sugar levels?

A: Official information confirms that corticosteroids can increase blood glucose concentrations, affecting the body’s ability to process carbohydrates. This effect requires attention, particularly for patients with diabetes.

Q: What is the role of Lenisolone in treating autoimmune diseases?

A: Lenisolone is indicated for the treatment of various autoimmune diseases. In these conditions, it functions as an immunosuppressant to control the abnormal immune response that is attacking the body's own tissues.

Q: Is Lenisolone a new drug, or has it been around for a while?

A: The active ingredient in Lenisolone, Prednisolone, is not a new medicine. It is a well-established, synthetic corticosteroid that has been in clinical use for many decades.

Q: Why do some forums mention 'steroid dependency' with drugs like Lenisolone?

A: This term commonly refers to the risk of adrenal suppression, a known effect of chronic corticosteroid use. Because of this risk, gradual dose reduction, known as tapering, is often required after chronic use to allow the body's natural production to recover.

Q: How long do most people stay on a course of Lenisolone?

A: The duration of treatment is highly dependent on the specific condition being treated and the patient’s response. It can range from short courses lasting only a few days to long-term chronic therapy spanning months or years.

Q: Why is Lenisolone sometimes prescribed in high doses initially?

A: According to official dosing guidelines, the initial dosage is often high to rapidly control the condition and achieve a prompt, satisfactory clinical response. Once the condition is controlled, the dose is then slowly reduced to the lowest effective maintenance level.

Q: What does Lenisolone do to the body at a cellular level?

A: At the cellular level, the active ingredient binds to specific receptors inside cells, which then modulates (changes) the expression of genes. This action is responsible for its potent anti-inflammatory and immunosuppressive effects.

Q: Can I drive or operate machinery while taking Lenisolone?

A: The medication can cause neurological side effects, including dizziness, vertigo, or changes in vision. If these effects occur, they may temporarily impair a person's ability to safely drive or operate heavy machinery.

How should Lenisolone be stored and disposed of?

The storage and disposal of Lenisolone (Prednisolone Acetate Ophthalmic Suspension) must follow official regulatory guidelines to maintain its stability and sterility.

Storage Requirements

  • Temperature: Store at controlled room temperature, generally up to 25 C (77 F).
  • Protection: The suspension must be protected from freezing and stored in an upright position.
  • Handling: The bottle must be shaken well before each use and kept tightly closed when not in use.
  • Child Safety: The medicine must be stored out of the reach of children.

Disposal and Stability

  • In-Use Stability: Regulatory documents commonly mandate that any unused product be discarded four weeks after the first opening.
  • Final Disposal: Unused or expired medication should be disposed of according to local regulations, often utilizing a drug take-back program or following instructions from a healthcare professional for proper handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lenisolone found in:

A-Z Index: